XENE > FDA gives OK for XEN496 in single pivotal Phase 3 trial for KCNQ2 epilepsy...
Based on the CC today, the CEO mentioned that he expects XENE will need to show about a 30-40% delta for XEN496 response vs. placebo in the P3 for KCNQ2-EE.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.